Results 31 to 40 of about 21,646 (232)

New indications for dabigatran: A suggestion from a drug use evaluation study

Journal of Research in Pharmacy Practice, 2017
Objective: Dabigatran etexilate is a novel oral anticoagulant with several advantages over warfarin such as no need for routine monitoring and fewer drug interactions. This drug was added to our hospital's formulary in 2012.
Farzaneh Ashrafi, Najmeh Rezaie, Sarah Mousavi   +2 more
doaj   +1 more source

Effect of Dabigatran on Clotting Time in the Clotpro Ecarin Clotting Assay: A Prospective, Single-Arm, Open-Label Study

Clinical and Applied Thrombosis/Hemostasis, 2020
Routine coagulation tests do not enable rapid, accurate determination of direct oral anticoagulant (DOAC) therapy. The ecarin clotting assay (ECA), performed on the ClotPro viscoelastic testing device, may enable sensitive and specific detection of ...
Alan Yean Yip Fong MRCP, Lee Len Tiong BPharm, Shirley Siang Ning Tan BPharm, Dominic Geruka BSc, Gerald Grino Apil BSc, Chee Wei Choo MSc, Tiong Kiam Ong MRCP   +6 more
doaj   +1 more source

Dabigatran étexilate et itraconazole

, 2022
International audienceDabigatran étexilate et itraconazole Le dabigatran étexilate est un substrat de la glycoprotéine P (P-gp), une pompe d'efflux située au niveau intestinal, alors que l'itraconazole est un inhibiteur puissant de la P-gp.
Legeay, Samuel, Faure, Sébastien
core   +1 more source

Volume replacement strategies do not impair the binding of dabigatran to idarucizumab: Porcine model of hemodilution.

PLoS ONE, 2019
BackgroundIdarucizumab is a humanized Fab fragment that specifically reverses dabigatran anticoagulation. In trauma, volume expanders are used for resuscitation to compensate for blood loss and hemorrhagic shock, but it is unknown whether volume ...
Oliver Grottke, Joanne van Ryn, Christian Zentai, Guanfa Gan, Markus Honickel, Rolf Rossaint, Hugo Ten Cate, Henri M H Spronk   +7 more
doaj   +1 more source

Comparison of benefit between dabigatran and warfarin among patients with atrial fibrillation: A systematic review

Archives of Pharmacy Practice, 2016
Warfarin is recognized as the standard antithrombotic agent for stroke prevention. However, new oral anticoagulant such as dabigatran constitutes huge improvement to compensate for the limitation of warfarin.
Amal K Sulieman
doaj   +1 more source

Thrombolysis in a stroke patient on dabigatran anticoagulation: case report and synopsis of published cases

, 2013
We present the case of an aphasic 77-year-old stroke patient with left distal M1 occlusion who received rt-PA for thrombolysis while on oral anticoagulant treatment with dabigatran (150 mg b.i.d.).
Baas, Horst, Mario Abruscato, Susanne Hövelmann, Pfeilschifter, Waltraud, Abruscato, Mario Giovanni Rosario, Hövelmann, Susanne, Horst Baas, Waltraud Pfeilschifter   +7 more
core   +1 more source

Determination of Dabigatran Concentration in Human Plasma and Breast Milk

International Journal of Analytical Chemistry, 2021
Venous thromboembolism (VTE) is an important cause of death following childbirth. Dabigatran etexilate can be a useful prophylaxis in susceptible women during the postpartum period. However, it is not clear whether dabigatran is excreted into breast milk
F. Sidgwick, A. Porter, P. Ayuk, F. Kamali, A. Truemann   +4 more
doaj   +1 more source

Difficult reversal of dabigatran with idarucizumab in a multiple-trauma patient: A question of dose?

Trauma Case Reports, 2021
Dabigatran is an oral anticoagulant directly acting as thrombin inhibitor. The monoclonal antibody idarucizumab was developed to reverse its anticoagulatory effects after application of a standardized dose.
Mathias Ströhle, Christopher Rugg, Stefan Schmid, Dietmar Fries, Elgar Oswald   +4 more
doaj   +1 more source

No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke

, 2012
Background: Dabigatran etexilate (DE) is a new oral direct thrombin inhibitor. Clinical trials point towards a favourable risk-to-benefit profile of DE compared to warfarin. In this study, we evaluated whether hemorrhagic transformation (HT) occurs after
Ferdinand Bohmann, Christian Foerch (149410), Edelgard Lindhoff-Last (149408), Ferdinand Bohmann (149406), Mirceska, Ana, Ana Mirceska, Förch, Christian, Waltraud Pfeilschifter, Pfeilschifter, Josef (Prof. Dr.), Bohmann, Ferdinand, Edelgard Lindhoff-Last, Waltraud Pfeilschifter (149411), Helmuth Steinmetz, Steinmetz, Helmuth, Christian Foerch, Helmuth Steinmetz (149409), Pfeilschifter, Waltraud, Josef Pfeilschifter, Josef Pfeilschifter (92946), Ana Mirceska (149407), Lindhoff-Last, Edelgard   +20 more
core   +1 more source

Dabigatran Level Before Reversal Can Predict Hemostatic Effectiveness of Idarucizumab in a Real-World Setting

Frontiers in Medicine, 2020
Background: Idarucizumab has been included in guidelines for the management of bleeding or surgical procedure in dabigatran-treated patients without need for biological monitoring.
Nicolas Gendron, Nicolas Gendron, Richard Chocron, Richard Chocron, Paul Billoir, Julien Brunier, Laurence Camoin-Jau, Marie Tuffigo, Dorothée Faille, Dorothée Faille, Dorian Teissandier, Juliette Gay, Juliette Gay, Emmanuelle de Raucourt, Emmanuelle de Raucourt, Ludovic Suner, Corentin Bonnet, Anne-Céline Martin, Anne-Céline Martin, Dominique Lasne, Chayma Ladhari, Aurélien Lebreton, Laurent Bertoletti, Laurent Bertoletti, Nadine Ajzenberg, Nadine Ajzenberg, Pascale Gaussem, Pascale Gaussem, Pierre-Emmanuel Morange, Pierre-Emmanuel Morange, Pierre-Emmanuel Morange, Véronique Le Cam Duchez, Alain Viallon, Pierre-Marie Roy, Pierre-Marie Roy, Agnès Lillo-le Louët, Agnès Lillo-le Louët, David M. Smadja, David M. Smadja, David M. Smadja   +39 more
doaj   +1 more source